在单心室循环衰竭中,-葡萄糖共运输体2抑制剂的心声图效应
Ralph M L Neijenhuis1,2, Madelien V Regeer1,2, Niki L Walker3
1CAHAL, Center for Congenital Heart Disease Amsterdam-Leiden, Leiden University Medical Center, Leiden, the Netherlands.
概括
-葡萄糖共运输体2抑制剂 (SGLT2i) 在单心力衰竭 (SVF) 患者中改善心室功能方面表现有前途. 在SGLT2i治疗的第一年内,人们注意到心声学上的改善,这表明了潜在的新治疗途径.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 遗传性心脏病是一种先天性心脏病.
背景情况:
- 单心室衰竭 (SVF) 构成循环损害的重大风险.
- 对于管理SVF.存在有限的药理选择.
- 这项研究调查了-葡萄糖共传输体2抑制剂 (SGLT2i) 对SVF患者腹腔功能的影响.
研究的目的:
- 评估SGLT2i治疗中SVF.患者心室功能回声学变化.
- 为了比较SGLT2i对心室功能的影响,在减弱 (SVFrEF) 和轻度减弱 (SVFpEF) 系统功能的患者中.
主要方法:
- 在SGLT2i上对成人先天性心脏病患者现实世界的国际注册表进行了回顾性分析.
- 纳入标准:SVF患者在指定的时间范围内进行了基线和随访心声图.
- 用混合效应模型评估了心室功能的纵向变化.
主要成果:
- 分析了13名SVF患者 (平均年龄21岁,61.5%的女性,76.9%的Fontan循环).
- 在100天内观察到末缩面积的显著减少和分数面积变化 (在SVFrEF中) 和自由壁应变的改善.
- 在SGLT2i治疗的最初100天内,同位体加速也显示出改善.
结论:
- 在SGLT2i治疗的第一年内,SGLT2i疗法在SVF患者中显示出心声学证据改善了心室功能.
- 这些发现表明SGLT2i可能是对SVF有益的药理干预措施.
- 需要进一步的研究来证实这些初步观察.
相关概念视频
01:29Heart Failure II: Pathophysiology
45
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
45
01:26Heart Failure Drugs: Inotropic Agents
732
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
732
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
01:30Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26
01:22Heart Failure Drugs: Diuretics
495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495
01:22Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435